Literature DB >> 8765264

Preoperative evaluation of ovarian tumors in the premenopause by transvaginosonography.

R G Osmers1, M Osmers, B von Maydell, B Wagner, W Kuhn.   

Abstract

OBJECTIVE: The aim of the study was to establish reproducible sonomorphologic criteria by use of transvaginosonography in the preoperative evaluation of ovarian tumors in the premenopause. STUDY
DESIGN: In a prospective study from 1987 to 1993 we investigated 1072 ovarian tumors. All tumors > or = 3 cm were included in the study. To avoid unnecessary operations, all tumors we rescanned after 6 weeks. The sonomorphologic criteria were correlated with the histologic findings.
RESULTS: A total of 4.3% of ovarian tumors in the premenopause were malignant. In the special group of sonographically simple ovarian cysts we found 0.8% malignancies. The incorporation of a control scan after 6 weeks in the management of ovarian cysts reduces the number of unnecessary operations on functional cysts. Only 5.5% of the functional tumors were operated on. The risk for malignancy in cystic-solid ovarian tumors is 17.0%, the highest of all sonomorphologic tumor types.
CONCLUSIONS: The use of reproducible sonomorphologic criteria in combination with a control scan in premenopausal women with ovarian cysts proved to be efficient to reduce the number of unnecessary operations and to evaluate the risk for malignancy.

Entities:  

Mesh:

Year:  1996        PMID: 8765264     DOI: 10.1016/s0002-9378(96)70157-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  Transvaginal ultrasound assessment of the premenopausal ovarian mass.

Authors:  Leeber Cohen
Journal:  J Assist Reprod Genet       Date:  2007-11-16       Impact factor: 3.412

2.  [Ultrasonographic clarification of adnexal findings].

Authors:  H J Prömpeler
Journal:  Radiologe       Date:  2011-07       Impact factor: 0.635

3.  Paraovarian cysts of neoplastic origin are underreported.

Authors:  Noam Smorgick; Arie Herman; David Schneider; Reuvit Halperin; Moty Pansky
Journal:  JSLS       Date:  2009 Jan-Mar       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.